ROIV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Roivant Sciences Ltd (ROIV) is not a strong buy for a beginner investor with a long-term strategy at this moment. Despite positive developments such as the Moderna settlement and bullish analyst ratings, the company's weak financial performance, insider selling, and lack of strong trading signals suggest it is better to hold off on investing right now.
The technical indicators are mixed. The MACD is slightly positive but contracting, RSI is neutral at 57.714, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below its pivot level of 28.53, with key support at 27.351 and resistance at 29.71. The recent price drop of -3.06% in the regular market and -2.12% in pre-market suggests short-term weakness.
The $2.25 billion settlement with Moderna resolves a significant overhang, allowing Roivant to focus on its clinical pipeline. Analysts have raised price targets, with JPMorgan increasing it to $33 and H.C. Wainwright to $34, citing the settlement and clinical readouts as positive developments.
The company's financial performance in Q3 2026 is extremely weak, with revenue down -77.83% YoY, net income down -256.98% YoY, and EPS down -265.22% YoY. Insider selling has surged by 4331.98% over the last month, indicating potential lack of confidence from insiders. Additionally, the stock has a high probability of declining in the next week (-7%) and month (-3.34%).
The financial performance for Q3 2026 is poor. Revenue dropped significantly by -77.83% YoY to $1.99 million. Net income plummeted to -$265.89 million, down -256.98% YoY. EPS dropped to -0.38, a decline of -265.22% YoY. Gross margin also decreased to 64.98, down -33.10% YoY.
Analysts are generally bullish on the stock, with multiple firms raising price targets recently. JPMorgan raised its target to $33, H.C. Wainwright to $34, and Citi to $35, citing the Moderna settlement and positive clinical data as key drivers. However, BofA maintains a Neutral rating, highlighting the removal of a near-term upside catalyst.
